Skip to main content
. 2021 Oct 26;148(20):dev199713. doi: 10.1242/dev.199713

Fig. 5.

Fig. 5.

Inhibition of retinoic acid receptor signaling prevents CXCL13 expression and development of FDCs in lymph nodes. (A) Heatmap showing mRNA expression levels of the listed genes in pLNs upon treatment for 7 and 10 days with BMS493, starting at day 4 after birth. (B,C) Immunofluorescence analysis of CXCL13 protein expression (in red) in peripheral lymph nodes of DMSO (control) and BMS493-treated mice at day 7 (B) and day 10 (C) after the start of treatment (age of mice is 11 and 14 days, respectively). (D,E) Immunofluorescence analysis of FDCs (8C12 in blue) in pLNs (D) and quantification of FDCs in lymph nodes (E) of DMSO (control) and BMS493-treated animals at day 10 after treatment. (F,G) mRNA expression levels of Rarb and Cxcl13 and volume ratio of B-cell follicle volume over total lymph node volume in pLNs of mice that were treated for 14 days with suboptimal doses of BMS493 versus DMSO (F) or for 7 days with BMS493 versus DMSO and left untreated for 21 days (G) starting at day 4 after birth. Data represent mean±s.e.m.; n≥3. *P<0.05; **P<0.01; ***P<0.001 (unpaired Student's t-test). ns, not significant (P>0.05).